The Efficacy of Mesenchymal Stem Cells in Therapy of Acute Kidney Injury Induced by Ischemia-Reperfusion in Animal Models

Autor: Tianbiao Zhou, Chunling Liao, Shujun Lin, Wenshan Lin, Hongzhen Zhong, Shuangyi Huang
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: Stem Cells International, Vol 2020 (2020)
Druh dokumentu: article
ISSN: 1687-966X
1687-9678
DOI: 10.1155/2020/1873921
Popis: Mesenchymal stem cells (MSCs), discovered and isolated from the bone marrow in the 1960s and with self-renewal capacity and multilineage differentiation potential, have valuable immunomodulatory abilities. Acute kidney injury (AKI) refers to rapid renal failure, which exhibits as quickly progressive decreasing excretion in few hours or days. This study was performed to assess the efficacy of MSCs in the treatment of AKI induced by ischemia-reperfusion using a meta-analysis method. A literature search using corresponding terms was performed in the following databases: Embase, Cochrane Library, PubMed, and ISI Web of Science databases up to Dec 31, 2019. Data for outcomes were identified, and the efficacy of MSCs for AKI was assessed using Cochrane Review Manager Version 5.3. Nineteen studies were eligible and recruited for this meta-analysis. MSC treatment can reduce the Scr levels at 1 day, 2 days, 3 days, 5 days, and >7 days (1 day: WMD=−0.56, 95% CI: -0.78, -0.34, P7 days: WMD=−0.22, 95% CI: -0.36, -0.08, P=0.002) and can reduce the levels of BUN at 1 day, 2 days, 3 days, and 5 days (1 day: WMD=−11.72, 95% CI: -18.80, -4.64, P=0.001; 2 days: WMD=−33.60, 95% CI: -40.15, -27.05, P7 days and alleviate the renal damage in animal models of AKI. In conclusion, MSCs might be a promising therapeutic agent for AKI induced by ischemia-reperfusion.
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje